Nasal Polyps Treatment Market by Type of Treatment (Pharmacological Therapies and Surgeries), End-User (Hospitals, Ambulatory Surgical Centers and Specialty Clinics) -Analysis & Forecast 2019-2030
Report ID : 169 | Published Date : Jan 2020 | Pages : 160 | Region : Global | Report Code : HS-2
Nasal Polyps Treatment Market Overview and Introduction
Nasal polyp is a noncancerous tumor growth in the nose lining. Polyp formation results due to inflammation in the nose. Large polyps of tear shape in the lining of sinus cause obstruction of airflow, leading to difficulty in breathing. Common symptoms linked with nasal polyps include blocked nose, headache, and sleep apnea. They are often associated with several sinus infections, allergic rhinitis, asthma, and aspirin allergy. The main aim of nasal polyps treatment is to reduce inflammation. Reduction in inflammation causes the shrinkage of polyps and later, they disappear. The first line of treatment for nasal polyp is medication and based on severity, surgeries can be the second line of treatment. Medication available for nasal polyps involves nasal corticosteroid, oral corticosteroid, antibiotics, and antihistamines. Functional Endoscopic Sinus Surgery (FESS) and polypectomy are among surgeries that are performed for the removal of nasal polyps.
The global nasal polyps treatment market is driven by increasing incidences of inflammatory and respiratory diseases such as chronic rhinosinusitis, asthma, and allergic rhinitis, which are commonly associated with the formation of nasal polyps. For instance, according to an article published by the American Academy of Allergy, Asthma & Immunology in 2017, around 28% to 40% of patients with nasal polyps are diagnosed with asthma. Moreover, the intensive research for novel treatment of nasal polyps is contributing to market growth. SINUVA, a sinus implant for the delivery of anti-inflammatory steroids was launched in 2018 by Intersect ENT, Inc for treating nasal polyps. However, complications associated with the treatment of nasal polyps, such as extensive bleeding, hamper the market growth.
The global nasal polyps treatment market is segmented by type of treatment, end-user, and region.
Nasal Polyps Treatment Market By Type of Treatment
Based on the type of treatment, the nasal polyps treatment market is segmented into pharmacological therapies and surgeries. The pharmacological therapies segment is estimated to account for the largest share in the global nasal polyps treatment market. The large share of this product segment can be attributed to the non-invasive nature of pharmacological therapies in which mainly topical and systemic corticosteroids are used to reduce the size of nasal polyps.
Nasal Polyps Treatment Market By End User
In terms of end-user, the nasal polyps treatment market can be segmented into hospitals, ambulatory surgical centers, and specialty clinics. The segment of hospitals is estimated to grow at a robust CAGR during the forecast period owing to increasing footfall of patients for treating nasal polyps at hospitals.
Nasal Polyps Treatment Market By Region
The global nasal polyps treatment market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the nasal polyps treatment market. North America will continue to dominate the global nasal polyps treatment market during the forecast period owing to factors such higher prevalence of respiratory infections, which are associated with nasal polyps, extensive technological advancement for treating nasal polyps and adoption of minimally invasive therapies by surgeons. However, Asia Pacific is expected to witness the highest CAGR, with market growth centered in China, Korea, Japan, and India. An increase in patient pool suffering from respiratory infections in Asia Pacific is the major factor for the growth of nasal polyps treatment market in this region.
Nasal Polyps Treatment Market Prominent Players
The prominent players in the global nasal polyps treatment market include OptiNose US, Inc., Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Sanofi, Novartis AG, Intersect ENT, Inc., and AstraZeneca , among others.